← Leaderboards
Robert K Bradley
Fred Hutchinson Cancer Research Center
$11,097,454
Attributed
$19,043,233
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,043,233 · 7
By mechanism
R01$17,424,256 · 5
P01$1,504,577 · 1
R56$114,400 · 1
Top collaborators
- Omar Abdel-Wahab19 shared
- Sergei Doulatov6 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Manoj M. Pillai$4,783,259
- Frederick Applebaum$175,711
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularRna SplicingMutationCellsGenesMessenger RnaDysmyelopoietic SyndromesAffectProteinsPhysiciansMutantScientistHematopoiesisProductionGeneticMutateNovel TherapeuticsPatient CareHematological DiseasePatternProteomeBiologyEventBlood Cells
Grant awards (35)
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$799,380
R01 · FY2025 · HL · contact PI
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia$719,414
R01 · FY2025 · CA · contact PI
Functional and molecular consequences of SF3B1 mutations in human hematopoietic stem cells$719,314
R01 · FY2025 · HL
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia$683,443
R01 · FY2024 · CA · contact PI
Interrogating the minor spliceosome to understand and treat leukemia$626,267
R01 · FY2024 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$791,584
R01 · FY2023 · HL · contact PI
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia$748,641
R01 · FY2023 · CA · contact PI
Interrogating the minor spliceosome to understand and treat leukemia$646,044
R01 · FY2023 · CA
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$633,700
R01 · FY2023 · HL · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$791,584
R01 · FY2022 · HL · contact PI
Interrogating the minor spliceosome to understand and treat leukemia$646,044
R01 · FY2022 · CA
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$636,097
R01 · FY2022 · HL · contact PI
Interrogating the minor spliceosome to understand and treat leukemia$659,229
R01 · FY2021 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$519,636
R01 · FY2021 · HL · contact PI
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$461,320
R01 · FY2021 · HL · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$276,769
R01 · FY2021 · HL · contact PI
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$174,777
R01 · FY2021 · HL · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$824,642
R01 · FY2020 · HL · contact PI
Interrogating the minor spliceosome to understand and treat leukemia$678,479
R01 · FY2020 · CA
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$654,938
R01 · FY2020 · HL · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$622,278
R01 · FY2019 · HL · contact PI
U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy$396,105
R01 · FY2019 · DK · contact PI
Project 2: Repeat derepression and RNA-mediated toxicity in FSHD$291,210
P01 · FY2019 · NS · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$628,575
R01 · FY2018 · HL · contact PI
U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy$396,105
R01 · FY2018 · DK · contact PI
Project 2: Repeat derepression and RNA-mediated toxicity in FSHD$295,412
P01 · FY2018 · NS · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$634,684
R01 · FY2017 · HL · contact PI
U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy$399,113
R01 · FY2017 · DK · contact PI
Project 2: Repeat derepression and RNA-mediated toxicity in FSHD$300,231
P01 · FY2017 · NS · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$644,704
R01 · FY2016 · HL · contact PI
U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy$341,375
R01 · FY2016 · DK · contact PI
Project 2: Repeat derepression and RNA-mediated toxicity in FSHD$300,427
P01 · FY2016 · NS · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$670,015
R01 · FY2015 · HL · contact PI
Project 2: Repeat derepression and RNA-mediated toxicity in FSHD$317,297
P01 · FY2015 · NS · contact PI
U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy$114,400
R56 · FY2014 · DK · contact PI